New pharmacological agent, SS-68 demonstrates promising results in the prevention of a wide range of heart rhythm disorders and conditions of reduced blood flow to the heart caused by clogged arteries ...
Rhythm will use Camurus' drug delivery technology, FluidCrystal ®, to formulate its once-weekly obesity drug candidate, setmelanotide (RM-493), then develop, manufacture, and commercialize the new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback